Merve Karayel Basar

Merve Karayel Basar

Auto-generated profile, based on publicly available information

Merve Karayel Basar

Department of Biochemistry and Molecular Biology, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, İstanbul, Turkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
IUIrep Uras
Irep Uras
MKMerve Karayel‐Basar
Merve Karayel‐Basar
BSBetul Sahin
Betul Sahin
ABAhmet Baykal
Ahmet Baykal
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder, characterized by memory deficit and dementia. AD is considered a multifactorial disorder where multiple processes like amyloid‐beta and tau accumulation, axonal degeneration, synaptic plasticity, and autophagic processes plays an important role. In this study, the spatial proteomic differences in the neonatal 5xFAD brain tissue were investigated using MALDI‐MSI coupled to LC‐MS/MS, and the statistically significantly altered proteins were associated with AD. Thirty‐five differentially expressed proteins (DEPs) between the brain tissues of neonatal 5xFAD and their littermate mice were detected via MALDI‐MSI technique. Among the 35 proteins identified, 26 of them were directly associated with AD. Our results indicated a remarkable resemblance in the protein expression profiles of neonatal 5xFAD brain when compared to AD patient specimens or AD mouse models. These findings showed that the molecular alterations in the AD brain existed even at birth and that some proteins are neurodegenerative presages in neonatal AD brain.Highlights: Spatial proteomic alterations in the 5xFAD mouse brain compared to the littermate. 26 out of 35 differentially expressed proteins associated with Alzheimer's disease (AD). Molecular alterations and neurodegenerative presages in neonatal AD brain. Alterations in the synaptic function an early and common neurobiological thread.

1 May 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
IKIrem Kiris
Irem Kiris
KSKrystyna Skalicka-Wozniak
Krystyna Skalicka-Wozniak
MBMerve Karayel Basar
Merve Karayel Basar
BSBetul Sahin
Betul Sahin
BGBUSRA GUREL
BUSRA GUREL
ABAhmet Baykal
Ahmet Baykal
Background: Alzheimer’s disease (AD) is one of the most prevalent diseases with rapidly increasing numbers, but there is still no medication to treat or stop the disease. Previous data on coumarins suggests that scopoletin may have potential benefits in AD. Objective: Evaluate the therapeutic potential of the coumarins with natural origin - scopoletin and pteryxin- in a 5xFAD mouse model of AD Methods: Both compounds were administered at two doses to 12-month-old mice, which represent severe AD pathology. The effects of coumarins were assessed on cognition in mouse experiments. Changes in the overall brain proteome were evaluated using LCMS/ MS analyses. Results: The Morris water maze test implicated that a higher dose of pteryxin (16 mg/kg) significantly improved learning, and the proteome analysis showed pronounced changes of specific proteins upon pteryxin administration. The amyloid-β precursor protein, glial fibrillary acid protein, and apolipoprotein E protein which are highly associated with AD, were among the differentially expressed proteins at the higher dose of the pteryxin. Conclusion: Overall, pteryxin may be evaluated further as a disease-modifying agent in AD pathology in the late stages of AD.

1 May 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
IKIrem Kiris
Irem Kiris
MBMerve Karayel Basar
Merve Karayel Basar
BSBetul Sahin
Betul Sahin
BGBUSRA GUREL
BUSRA GUREL
JCJulide Coskun
Julide Coskun
ABAhmet Baykal
Ahmet Baykal
Background:: Alzheimer’s disease is one of the leading health problems characterized by the accumulation of Aβ and hyperphosphorylated tau that account for the senile plaque formations causing extensive cognitive decline. Many of the clinical diagnoses of Alzheimer’s disease are made in the late stages, when the pathological changes have already progressed. Objective:: The objective of this study is to evaluate the promising therapeutic effects of a natural compound, lycoramine, which has been shown to have therapeutic potential in several studies and to understand its mechanism of action on the molecular level via differential protein expression analyses. Method:: Lycoramine and galantamine, an FDA approved drug used in the treatment of mild to moderate AD, were administered to 12 month-old 5xFAD mice. Effects of the compounds were investigated by Morris water maze, immunohistochemistry and label- free differential protein expression analyses. Results:: Here we demonstrated the reversal of cognitive decline via behavioral testing and the clearance of Aβ plaques. Proteomics analysis provided in-depth information on the statistically significant protein perturbations in the cortex, hippocampus and cerebellum sections to hypothesize the possible clearance mechanisms of the plaque formation and the molecular mechanism of the reversal of cognitive decline in a transgenic mouse model. Bioinformatics analyses showed altered molecular pathways that can be linked with the reversal of cognitive decline observed after lycoramine administration but not with galantamine. Conclusion:: Lycoramine shows therapeutic potential to halt and reverse cognitive decline at the late stages of disease progression, and holds great promise for the treatment of Alzheimer’s disease.

7 February 2022 in Molecular Omics
Verified
Journal Article
Closed access
PDF file
MKMerve Karayel-Basar
Merve Karayel-Basar
IUIrep Uras
Irep Uras
IKIrem Kiris
Irem Kiris
BSBetul Sahin
Betul Sahin
EAEmel Akgun
Emel Akgun
ABAhmet Baykal
Ahmet Baykal
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder that occurs with the increase of CAG trinucleotide repeats in the huntingtin gene. To understand the mechanisms of HD, powerful proteomics techniques, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) were employed. However, one major drawback of these methods is loss of the region-specific quantitative information of the proteins due to analysis of total tissue lysates. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is a MS-based label-free technique that works directly on tissue sections and gathers m/z values with their respective regional information. In this study, we established a data processing protocol that includes several software programs and methods to determine spatial protein alterations between the brain samples of a 12 month-old YAC128 HD mouse model and their non-transgenic littermates. 22 differentially expressed proteins were revealed with their respective regional information, and possible relationships of several proteins were discussed. As a validation of the MALDI-MSI analysis, a differentially expressed protein (GFAP) was verified using immunohistochemical staining. Furthermore, since several proteins detected in this study have previously been associated with neuronal loss, neuronal loss in the cortical region was demonstrated using an anti-NeuN immunohistochemical staining method. In conclusion, the findings of this research have provided insights into the spatial proteomic changes between HD transgenic and non-transgenic littermates and therefore, we suggest that MALDI-MSI is a powerful technique to determine spatial proteomic alterations between biological samples, and the data processing that we present here can be employed as a complementary tool for the data analysis.


26 June 2024 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
PDF file
IKİrEm Kiriş
İrEm Kiriş
MBMerve Karayel Başar
Merve Karayel Başar
BGBUSRA GUREL
BUSRA GUREL
Tomasz MroczekTomasz Mroczek
Tomasz Mroczek
ABAhmet Baykal
Ahmet Baykal
Background/aim: Alzheimer’s disease (AD), one of the most common health issues, is characterized by memory loss, severe behavioral disorders, and eventually death. Despite many studies, there are still no drugs that can treat AD or stop it from progressing. Previous in vitro tests showed that O-demethyl galantamine (ODG) might have a therapeutic potential owing to its 10 times higher acetylcholinesterase inhibitory activity than galantamine (GAL). Materials and methods: We aimed to assess effect of ODG on a molecular level 12-month-old 5xFAD Alzheimer’s mouse model. To this end, following the administrations of ODG and GAL, used as a positive control, protein alterations were investigated in the brain’s cortex, hippocampus, and cerebellum regions. Surprisingly, GAL altered proteins prominently in the cortex, while ODG exclusively exerted its effect on the cerebellum. Results: GNB1, GNB2, NDUFS6, PAK2, and RhoA proteins were identified as the top 5 hub proteins in the cerebellum of ODG treated mice. Re-regulation of these proteins through Ras signaling and retrograde endocannabinoid signaling pathways that were found to be enriched, might contribute to reversing AD-induced molecular changes.Conclusion: We suggest that, since it aims specifically the cerebellum, ODG may be further evaluated for combination therapies for AD.